Lipigon aviserade under förra veckan positiva säkerhetsdata med Lipisense i klinisk fas I.
Strong USD should keep supporting Q4 results... ...
Redeye sees the FDA's fast track designation for EVX-01 as a validation of the personalised vaccin a...
Redeye comments on the events of the fourth quarter, including progress with the main candidate Pulm...
Kraftig tillväxt till följd av höga investeringar i marknadsföring… Nettoomsättningen i kvartalet up...
Redeye sees no big drama in Acuvi’s two announcements yesterday.
Redeye concludes that Q4 was more or less exactly in line with Redeye’s sales estimates – both for A...
Q4 report due 8 February We forecast sales of SEK 447m, EBITA of SEK 53m Share trading at '23e-'24e ...
Redeye comments on the new positive phase I data from the Lipisense trial.
We forecast a seasonally strong Q4, with organic growth of 14%, supported by the FIFA World Cup, the...
Prelim. ARR of DKK 71m corresponds to 28% y-o-y growth New '22 adj.
Q4 report due 09 Feb EBIT cut by 3%, 6%, and 4% for '22e-'24e Trading at 9x P/E with 9% FCF yield 20...
Redeye comments on Isofol’s board proposing a liquidation of the company after considering different...
Upprepar finansiella mål Under kapitalmarknadsdagen den 17:e januari förmedlade Systemair sin strate...
Targets SEK 2bn in revenue and adj. EBITA margin 6% in 2023 Targets 10% org.
Solteq presented its new strategy in its CMD 2023 event, reiterating near-term challenges and settin...
Q4 report due 21 February We forecast sales of SEK 190m, adj.
CEO to step down after 9 years... .. and Chairman of the board resigns with immediate effect New CEO...
Redeye updates its estimates ahead of the Q4 report (due 22 February) with slight downward adjustmen...
We expect Rovio's Games gross bookings to decline by 9% y/y organically in Q4, broadly in line with ...
